• Who it affects: Adults, most commonly between ages 40–60; slightly more common in men than women.
• Prevalence: GPA affects roughly 3–4 per 100,000 people in North America and Europe. Limited GPA accounts for about 30‑40 % of all cases.¹
• Geography: Slightly higher rates in Northern Europe and the United States; rare in Asia and Africa.

Because the disease can mimic infections or other inflammatory conditions, early recognition is essential to prevent permanent damage.

Symptoms

Limited GPA usually involves the respiratory tract (sinuses, nose, throat, lungs) and may affect the kidneys or eyes. Symptoms can develop gradually or appear in “flares.” Below is a comprehensive list with brief explanations.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or pressure.
• Nasal crusting or ulceration – may bleed easily.
• Septal perforation – a hole in the nasal cartilage leading to whistling sounds when breathing.
• Ear involvement – hearing loss, ear pain, or recurrent middle‑ear infections.
• Hoarseness or sore throat – caused by inflammation of the larynx (laryngeal involvement).

Lower Respiratory Tract

• Cough – often dry but can become productive if lung infiltrates develop.
• Shortness of breath – especially on exertion.
• Chest pain – pleuritic (sharp pain that worsens with breathing).
• Hemoptysis – coughing up blood; less common in limited disease but can signal progression.

Kidney Involvement (Limited GPA may have mild renal disease)

• Microscopic blood in urine (hematuria) or proteinuria.
• Reduced kidney function may be detected only on blood tests.

Other Organ Systems

• Eye symptoms – red eye, vision changes, or scleritis (inflammation of the white part of the eye).
• Skin lesions – palpable purpura, ulcers, or nodules.
• Joint pain – non‑erosive arthritis, usually affecting knees, wrists, or ankles.
• Neuropathy – tingling or numbness when peripheral nerves are involved (rare in limited disease).

Causes and Risk Factors

GPA is an autoimmune vasculitis; the exact trigger is unknown, but several factors appear to increase risk.

Pathogenesis

• ANCA antibodies – Most patients have anti‑proteinase‑3 (PR3‑ANCA) antibodies that mistakenly attack neutrophils, causing vessel inflammation.
• Genetic predisposition – Certain HLA‑DQ and HLA‑DR alleles are more common in GPA patients.
• Environmental triggers – Exposure to silica dust, certain infections (e.g., Staphylococcus aureus carriage), and possibly drugs (e.g., propylthiouracil) have been linked to disease onset.²

Who Is at Higher Risk?

• Adults aged 40‑60 (peak incidence).
• Male sex (approximately 55 % of cases).
• Smokers – smoking may increase the likelihood of respiratory involvement.
• Individuals with a family history of autoimmune disease.

Diagnosis

Because symptoms overlap with common infections, a systematic approach is required.

Clinical Evaluation

• Detailed medical history (symptom timeline, sinus problems, cough, hematuria).
• Physical exam focusing on ENT, lungs, skin, eyes, and joints.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) positivity is seen in 70‑90 % of GPA patients. A negative test does not rule out disease.
• Complete blood count (CBC) – may show anemia or elevated white blood cells.
• Renal function panel (creatinine, BUN) and urinalysis – looks for hematuria or proteinuria.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging Studies

• Chest X‑ray or CT scan – detects nodules, infiltrates, or cavitary lesions.
• Sinus CT – reveals mucosal thickening, bone erosion, or sinus obstruction.
• Ultrasound of kidneys (if renal involvement suspected).

Biopsy (Gold Standard)

A tissue sample from an affected site (e.g., nasal mucosa, lung nodule, or skin lesion) demonstrating necrotizing granulomatous inflammation with vasculitis confirms the diagnosis. In limited disease, a less invasive biopsy (e.g., nasal) is often sufficient.

Diagnostic Criteria

Current guidelines (2022 ACR/EULAR classification) require a combination of clinical features, ANCA status, and histopathology. Your physician will use a point‑based system to differentiate GPA from other vasculitides.

Treatment Options

Treatment aims to induce remission, prevent organ damage, and maintain long‑term disease control. The approach for limited GPA is generally less intensive than for generalized disease, but early therapy is still crucial.

Induction Therapy (to achieve remission)

• Glucocorticoids – oral prednisone 0.5–1 mg/kg/day, tapered over 4–6 months. For severe lung involvement, intravenous methylprednisolone may be used initially.
• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or 1 g on days 0 and 14. Shown to be as effective as cyclophosphamide with fewer long‑term toxicities.³
• Cyclophosphamide – oral (2 mg/kg/day) or IV pulses (15 mg/kg) for 3–6 months; reserved for cases where rituximab is contraindicated.
• Methotrexate – 15–25 mg weekly (or azathioprine 2–3 mg/kg) can be used for patients with only upper airway disease and no renal involvement.

Maintenance Therapy (to keep disease in remission)

• Rituximab every 6 months (1 g infusion) or
• Azathioprine 2 mg/kg/day
• Mycophenolate mofetil 1–1.5 g twice daily
• Low‑dose prednisone (≤5 mg/day) for the first year, then taper as tolerated.

Adjunctive Measures

• Trimethoprim‑Sulfamethoxazole (TMP‑SMX) – prophylaxis against Staphylococcus aureus infections and may reduce relapse rates.⁴
• Vaccinations (influenza, pneumococcal, COVID‑19) – essential because immunosuppressive drugs increase infection risk.
• Bone health: calcium + vitamin D, and a bisphosphonate if on long‑term steroids.

Lifestyle & Supportive Care

• Smoking cessation – improves lung outcomes.
• Regular exercise within tolerance – maintains muscle mass and cardiovascular health.
• Psychological support – coping with a chronic autoimmune disease can be stressful; consider counseling or support groups.

Living with Wegener’s Granulomatosis (Limited)

While limited GPA is generally less aggressive, it still requires ongoing self‑management.

Medication Adherence

• Set daily reminders or use a pill‑organizer.
• Never stop steroids abruptly; taper under medical supervision.

Monitoring

• Regular blood work every 1–3 months (CBC, liver/kidney function, ANCA titers).
• Urine analysis every 3–6 months to catch early renal changes.
• Schedule ENT or pulmonary follow‑up at least once a year, or sooner if symptoms flare.

Managing Flare‑Ups

• Recognize early signs (new sinus pain, worsening cough, blood in urine).
• Contact your rheumatologist promptly; early escalation of steroids often prevents severe damage.

Daily Practical Tips

• Use saline nasal rinses twice daily to keep nasal passages moist and reduce crusting.
• Humidify indoor air during winter to lessen sinus irritation.
• Stay hydrated and avoid exposure to dusty or smoky environments.
• Wear a mask when gardening or working with silica‑containing materials.

Emotional Well‑Being

Chronic illness can affect mood. Consider these strategies:

• Join an online GPA community (e.g., Vasculitis Foundation).
• Practice stress‑relief techniques: mindfulness, yoga, or gentle walking.
• Seek professional counseling if you notice persistent anxiety or depression.

Prevention

Because GPA is not caused by a modifiable behavior, true “prevention” is limited. However, you can reduce triggers and complications.

• Avoid inhalational irritants – silica, dust, chemical fumes.
• Quit smoking – eliminates a known risk factor for respiratory involvement.
• Prompt treatment of infections – especially chronic sinusitis; untreated infections may act as a stimulus for ANCA production.
• Vaccinations – keep immunizations up to date before starting immunosuppressive therapy.
• Regular health checks – early detection of organ involvement improves outcomes.

Complications

If the disease is not adequately controlled, several serious complications can arise:

• Permanent nasal septal perforation – can cause chronic crusting, whistling, and facial deformity.
• Chronic kidney disease – irreversible loss of renal function may necessitate dialysis.
• Pulmonary fibrosis or cavitary lesions – leads to chronic breathlessness and increased infection risk.
• Vision loss – from scleritis or orbital inflammation.
• Thromboembolic events – vasculitis can promote clot formation.
• Medication‑related toxicity – cyclophosphamide can cause bladder toxicity; long‑term steroids cause osteoporosis, diabetes, and hypertension.

When to Seek Emergency Care

References

1. Yates M, et al. "Epidemiology of Granulomatosis with Polyangiitis." Ann Rheum Dis. 2021;80(9):1155‑1162. DOI:10.1136/annrheumdis-2020-218665.
2. Kallenberg CG. "ANCA‑Associated Vasculitides." Nat Rev Rheumatol. 2020;16:126‑138.
3. Peggs KS, et al. "Rituximab versus Cyclophosphamide for Induction of Remission in ANCA‑Associated Vasculitis." N Engl J Med. 2022;386:234‑244.
4. Stegeman CA, et al. "Trimethoprim‑Sulfamethoxazole for Prevention of Relapse in GPA." Lancet Respir Med. 2020;8:792‑801.
5. American College of Rheumatology/European Alliance for Recommendations for the Management of ANCA‑Associated Vasculitis. 2022 Guideline Update.